Inhibrx director granted 15,000 stock options

Inhibrx Biosciences director Kristiina Vuori, MD, received a grant of stock options for 15,000 shares of common stock.

The filer has since corrected this document, so the figures below are the ones originally reported and some of them may have changed. Read the amended Form 4/A for what the company says now.

Rhea-AI Filing Summary

Inhibrx Biosciences director Kristiina Vuori, MD, received a grant of stock options for 15,000 shares of common stock. The options have an exercise price of $95.22 per share, become fully exercisable on June 3, 2027, subject to her continued service, and expire on June 3, 2036.

Insights

Equity compensation analyst

Routine director stock option grant with long-term vesting.

Inhibrx Biosciences, Inc. granted director Kristiina Vuori, MD, stock options for 15,000 shares of common stock at an exercise price of $95.22 per share. The grant is classified as a compensation-related acquisition, not an open-market purchase.

The options become fully exercisable on June 3, 2027, conditional on her continued service, and expire on June 3, 2036. This structure aligns her incentives with long-term company performance and is typical for board-level equity awards.

There are no same-day sales, tax withholdings, or related derivative positions shown, so this filing mainly updates the record of her option holdings. Future company filings may provide additional context on her overall equity position and any subsequent exercises.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Vuori Kristiina MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Key Figures

Option grant size: 15,000 options Exercise price: $95.22 per share Underlying shares: 15,000 shares +2 more

5 metrics

Option grant size 15,000 options Stock Option (right to buy) granted to director

Exercise price $95.22 per share Conversion or exercise price of options

Underlying shares 15,000 shares Common stock underlying the options

Vesting date June 3, 2027 Fully exercisable on this date, subject to continued service

Expiration date June 3, 2036 Option expiration

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 95.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Inhibrx Biosciences (INBX) report for Kristiina Vuori, MD?

Inhibrx Biosciences reported a stock option grant to director Kristiina Vuori, MD, for 15,000 shares. The options are a compensation-related award, not an open-market purchase or sale, and give her the right to buy common shares at a fixed exercise price.

How many Inhibrx Biosciences (INBX) shares are covered by the new stock options?

The new stock option award covers 15,000 shares of Inhibrx Biosciences common stock. These options allow Kristiina Vuori, MD, to purchase up to that number of shares once vested, providing equity-based incentive aligned with the company’s future performance.

What is the exercise price of Kristiina Vuori’s Inhibrx (INBX) stock option grant?

The stock options granted to Kristiina Vuori, MD, have an exercise price of $95.22 per share. This is the price she must pay per share to exercise the options and acquire Inhibrx Biosciences common stock after vesting.

When do Kristiina Vuori’s Inhibrx Biosciences (INBX) options vest and become exercisable?

The options will be fully exercisable on June 3, 2027, subject to her continued service. This means she must remain in her role through that date to gain full rights to exercise all 15,000 optioned shares.

When do the newly granted Inhibrx Biosciences (INBX) stock options expire?

The stock options granted to Kristiina Vuori, MD, expire on June 3, 2036. After that expiration date, any unexercised portion of the 15,000 options will lapse, and she will no longer be able to purchase shares under this grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vuori Kristiina MD

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 N. TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		15,000		06/03/2027(1)	06/03/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

	/s/ Kelly Deck, as attorney-in-fact to Kristiina Vuori	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)